– USA, IL – Turner Scientific, a world leader in nonclinical hearing research, has named David Hicks, M.D. as CEO. Dr. Hicks, formerly Turner Scientific’s business development manager for contract research, will continue to oversee the marketing of the company’s research operations. He will also assume responsibility for the development of the company’s noise and vibration monitoring services, corporate strategy, human resources, and financial operations.
“We are very excited to promote David to the role of CEO,” said Turner Scientific’s CSO and founder, Jeremy Turner, PhD. “This is a very promising time for Turner Scientific, as we have also hired two scientists to complement our research staff, and are planning in the imminent move to a much larger research facility. David’s leadership and his understanding of the consequences of hearing loss and tinnitus make him an excellent choice to guide this continued growth.”
With experience in both clinical hearing disorders and nonclinical auditory science, Dr. Hicks is excited to bridge these disciplines while collaborating with biotechnology companies, pharmaceutical companies, and academic labs. “Dr. Turner has dedicated his career to studying the ears, and has assembled a team of auditory researchers that is unmatched by any other contract research organization,” he says. “It is a privilege to lead this team. This is a period of rapid innovation for hearing treatments, and I greatly enjoy being a part of this growth.”
Prior to Turner Scientific, Dr. Hicks served as Director of Clinical and Business Operations at Fortuna Fix, Inc., and Vice President of Fleetridge Pacific, a healthcare mergers and acquisitions advisory firm. As a medical doctor, he received training in ear-related disorders during his residency in otolaryngology.
About Turner Scientific
Turner Scientific is a nonclinical contract research organization specializing in auditory sciences and a consultant in noise and vibration control to animal research facilities. The company offers a full range of auditory testing methods, including behavioral audiometry, tinnitus testing, auditory brainstem response testing, cytocochleograms, ribbon synapse analysis, and cochlear explant studies. Efficacy studies are conducted for leading biotechnology companies, pharmaceutical companies, and academic labs developing novel treatments for the ears. Ototoxicity analysis is provided for developers of drugs and manufacturers of industrial chemicals. Turner Scientific is also a leading provider of consultancy and monitoring services to minimize the confounding influences of noise and vibration exposure of animals in research facilities.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.